Avalyn Pharma Inc.
AVLN evidence brief
What we can confirm
- BioSniper Score:
- 10.0 / 10
- Market Cap:
- $1.54B
What it means
What to watch
Prepared research question
What matters most for AVLN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AVLN
Avalyn Pharma Inc. (AVLN) is a clinical-stage biopharmaceutical company developing inhaled therapies for pulmonary fibrosis, with lead candidates AP01 and AP02 in Phase 2 trials and a cash runway projected into 2029.
Key risk: No profitability to date
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$1.54B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Avalyn Pharma Inc. (AVLN) is a clinical-stage biopharmaceutical company developing inhaled therapies for pulmonary fibrosis, with lead candidates AP01 and AP02 in Phase 2 trials and a cash runway projected into 2029.
- Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 [news · 2026-08-12].
- Cash, cash equivalents and marketable securities of $413.5 million as of Q2 2026, with cash runway projected into 2029 [news · 2026-08-12].
- Accumulated deficit of $265.4 million as of December 31, 2025 [sec · filed 2026-04-29].
- Net income of -$28.9M and shareholders' equity of $398.3M as of 2026-06-30 [sec].
- Pipeline includes AP02 (inhaled nintedanib) Phase 2 proof-of-concept study (AURA-IPF) started March 2026, and AP03 (inhaled fixed-dose combination) in development [sec · filed 2026-04-29][catalyst].
What works
- Strong cash position of $413.5 million as of Q2 2026 provides runway into 2029, supporting ongoing clinical programs [news · 2026-08-12].
- Proprietary inhaled delivery platform may reduce systemic side effects compared to oral antifibrotics, addressing a key tolerability issue [sec · filed 2026-04-23].
- Experienced leadership team with deep expertise in respiratory medicines and inhaled therapeutics [sec · filed 2026-04-29].
What to weigh
- Company has never been profitable and reported an accumulated deficit of $265.4 million as of December 31, 2025; expenses expected to increase substantially as trials advance [sec · filed 2026-04-29].
- Heavy dependence on success of lead candidates AP01 and AP02; failure or delays would materially harm the business [sec · filed 2026-04-29].
- Operating losses may fluctuate significantly and additional funding will be needed; capital may not be available on acceptable terms [sec · filed 2026-04-29].
From the filings
Quoted directly from source documents.
AP01 Phase 2b enrollment completed with 398 patients; topline data expected H2 2027
“Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027”
News · August 12, 2026
Cash position of $413.5 million as of Q2 2026
“Ended the second quarter of 2026 with $413.5 million in cash, cash equivalents and marketable securities; cash runway projected into 2029”
News · August 12, 2026
Accumulated deficit of $265.4 million as of December 31, 2025
“As of December 31, 2025, we had an accumulated deficit of $265.4 million.”
SEC filings · April 29, 2026
Dependence on lead candidates AP01 and AP02
“We are substantially dependent on the success of our lead candidates, AP01 and AP02.”
SEC filings · April 29, 2026
Catalyst timeline
- 2024-04-03 · Phase 2b start for AP01 (MIST trial) — A randomized, double-blind, placebo-controlled Phase 2b study of pirfenidone solution for inhalation in participants with PPF.
- 2025-04-17 · Phase 2 start for open-label extension (SAIL) — A multinational, long-term, safety and tolerability open-label extension study of subjects from Avalyn inhaled antifibrotic studies.
- 2026-03-10 · Phase 2 start for AP02 (AURA-IPF) — A randomized, double-blind, placebo-controlled Phase 2 proof-of-concept study of nintedanib solution for inhalation in IPF patients.
Risks & what to watch (4)›
Key risks
- No profitability to date — Accumulated deficit of $265.4M as of Dec 31, 2025; may never achieve profitability [sec · filed 2026-04-29].
- Single-pipeline dependency — Business materially harmed if AP01 or AP02 fail or are delayed [sec · filed 2026-04-29].
- Need for additional funding — Substantial additional funding required; may not be available on acceptable terms [sec · filed 2026-04-29].
- Clinical trial execution risk — Expenses will increase substantially as trials advance; operating losses may fluctuate [sec · filed 2026-04-29].
What to watch
- Topline data from AP01 Phase 2b MIST trial expected in the second half of 2027 [news · 2026-08-12].
- Progress of AP02 Phase 2 proof-of-concept study (AURA-IPF) initiated March 2026 [catalyst].
- Cash burn rate and whether cash runway extends into 2029 as projected [news · 2026-08-12].
- Any updates on AP03 fixed-dose combination development [sec · filed 2026-04-29].
Sources: Catalysts · News · SEC filings · Generated October 13, 2026 · How we verify sources →
Run Avalyn Pharma Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Avalyn Pharma Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.07 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
4 buys · 0 sells (180d)
Financials
Frequently asked questions
What is the AI investment thesis for Avalyn Pharma Inc.?
Avalyn Pharma Inc. (AVLN) is a clinical-stage biopharmaceutical company developing inhaled therapies for pulmonary fibrosis, with lead candidates AP01 and AP02 in Phase 2 trials and a cash runway projected into 2029.
Who is the CEO of Avalyn Pharma Inc.?
Ms. Lyn Baranowski is the chief executive officer of Avalyn Pharma Inc. (AVLN).
Where is Avalyn Pharma Inc. headquartered?
Avalyn Pharma Inc. (AVLN) is headquartered in Boston, MA, United States.
What therapeutic areas does Avalyn Pharma Inc. focus on?
Avalyn Pharma Inc. develops therapies across Immunology, Respiratory, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.